PRODUCT
SEC Staff Recommends Enforcement Action Against Allarity Over Potential Federal Securities Laws Violations
Allarity Therapeutics, SEC, Enforcement Action, Federal Securities Laws, Violations, Wells Notice, FDA, Dovitinib, Stenoparib
Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment
Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Cancer Treatment, Global Licensing Agreement, FS001
J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment
Carvykti, Multiple Myeloma, Phase III, CARTITUDE-4, FDA Approval, BCMA-Targeted Therapy, Johnson & Johnson, Legend Biotech
Taysha Gene Therapies Announces Positive Results for TSHA-102 in Rett Syndrome Trials
Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Motor Skills, Communication, Autonomic Function, Seizures
Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor
Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology
Eko Health Secures $41 Million to Expand AI-Powered Stethoscope Business Globally
Eko Health, AI Stethoscope, Telehealth, Healthcare Technology, Funding
ConcertAI Partners with NVIDIA, Unveils Advanced AI Tools for Oncology Research and Treatment
ConcertAI, NVIDIA, AI tools, oncology research, clinical simulations, CARA AI platform, multi-modal oncology data, clinical trials, patient outcomes
Biogen and Ionis’ ALS Treatment Qalsody Receives European Commission Approval
Biogen, Ionis, Qalsody, ALS, European Commission, Marketing Authorization, Rare Disease, SOD1-ALS, Neurofilament, Clinical Trials
Merck & Co. Revives Ophthalmology Efforts with $3 Billion EyeBio Acquisition ###
Merck & Co., EyeBio, Ophthalmology, Trispecific antibody, Restoret, Acquisition, Biotechnology, Pharmaceuticals
Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis
Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.